Argus Research downgraded Colgate-Palmolive Co (CL) to Hold from Buy on December 10, 2025. The stock is currently priced at $78.14. This downgrade reflects increased caution regarding the company's outlook, possibly due to competitive pressures and market conditions that may impact performance.
Colgate-Palmolive Co, headquartered in New York City, engages in the manufacturing and distribution of consumer products across various segments, including Oral Care, Personal Care, Home Care, and Pet Nutrition. The company has a market capitalization of $62.3 billion and a trailing P/E ratio of 21.45. Its earnings per share (EPS) stands at $3.57, with a dividend yield of 273.3%.
Upcoming earnings reports are scheduled for April 23, 2026, with an EPS estimate of $0.97 and revenue expectations of $5.3 billion, and July 30, 2026, with an EPS estimate of $0.99 and revenue expectations of $5.4 billion.
The analyst consensus as of December 1, 2025, includes 6 Strong Buy, 12 Buy, 10 Hold, 1 Sell, and 1 Strong Sell recommendations, indicating a general Buy outlook among analysts. Recent actions include an upgrade from RBC Capital to Outperform and a maintenance of ratings from Barclays and UBS.
Analyst ratings are informed opinions based on research and financial models. They should be considered alongside company fundamentals, competitive positioning, and broader industry trends.